Figure 5.
Effect of CF101 on the development of primary tumour and liver metastasis in CT-26 colon carcinoma-bearing mice. For the primary tumour model CT-26 cells were subcutaneously injected to the flank of nude mice, and for the liver metastatic model CT-26 cells were injected beneath the spleen capsule. For both models, treatment was initiated 1 day after tumour cell inoculation and included daily oral administration of CF101 (10 μg kg−1) till the mice were killed.